PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery
News Jan 17, 2008
Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen's Nuclear Hormone Receptor proteins and Lanthascreen® assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor screening tools; specifically its PamChip® applications and PamStation® instrumentation.
This creates a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease. The current market for nuclear receptor targeted drugs is estimated to be 10-15% of the $400 billion global pharmaceutical market.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019